The effects of KIT D816V-targeted therapy on the incidence of anaphylaxis are unknown.<h4>Methods</h4>We describe anaphylaxis events occurring in the study population of PIONEER (NCT03731260) during the 12-week screening and/or 24-week treatment period. Here, KIT is linked to anaphylaxis.